Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

BioPharma Dive stories

Nov 16, 2026

Sofinnova Partners raises €725M crossover fund for late-stage European biotechs

Paris-based Sofinnova Partners secured €725 million ($815 million) for its second crossover fund targeting late-stage European biopharma companies, addressing a financing gap in the sector.

Nov 16, 2026·3 sources
00

Top claims

  • ▪Sofinnova Crossover II has already deployed capital into clinical-stage biotechnology companies CellCentric and Hemab Therapeutics
  • ▪Sofinnova Partners partner Kinam Hong led an initial investment in immune drugmaker Abivax, which later reached a public market valuation of approximately $7 billion
  • ▪Sofinnova Partners partner Kinam Hong stated that Europe faces a scale-up financing problem rather than an innovation problem for life sciences companies

Topics

Biotech innovationBiotechnologyPharmaceutical IndustryVenture capital funding

Related entities

EuropeParis